Q-omics provides the consensus-scored CLDN17 profile across patient tissues and cancer cell-line models. CLDN17 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CLDN17 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, CLDN17 RNA expression shows 7,760 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UVM, HNSC, and ESCA as cancer lineages where CLDN17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLDN17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLDN17 survival associations across molecular data types. CLDN17 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLDN17 RNA expression–survival associations across cancer types. High CLDN17 expression shows unfavorable associations in UVM, KIRC, KIRP, SKCM, BLCA and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CLDN17 RNA expression.
This table summarizes CLDN17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CLDN17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLDN17 shows lower tumor expression in HNSC, KIRC, STAD and COAD and higher tumor expression in LUSC and KICH. The HNSC box plot shows higher CLDN17 RNA expression in normal versus tumor tissue (log2 FC = −1.852, t-test p < 0.001).
This table shows molecular features associated with CLDN17 in patient tissues and cancer cell lines. In patient samples, CLDN17 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CLDN17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
